The system’s workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day.
The system is expected to be priced under $125,000 with individual run prices ranging from $400-$750.
Illumina president and CEO Jay Flatley said MiSeq takes advantage of recent advances in our sequencing chemistry, including significantly faster cycle times and simplified sample preparation, to deliver next-generation sequencing to individual researchers, especially those who currently use capillary electrophoresis (CE) sequencers.
"Users will also benefit greatly from MiSeq’s compact footprint of approximately 2 feet square, intuitive user interface, simple workflow, and low capital and run price," Flatley said.
"The platform will enable applications such as amplicon sequencing, clone checking, small genome sequencing, ChIP-Seq, and RNA-Seq, all with a single, integrated instrument and at a fraction of current costs and time."
Using Illumina’s TruSeq chemistry, MiSeq provides users the flexibility to optimize run conditions to suit their particular applications.
The system also eliminates the need for additional instruments to operate other NGS platforms and particularly that rely on emulsion PCR (ePCR) for sample amplification.
